Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532071 · ClinicalTrials.gov registry record · Phase 2
Advanced Imaging for Pulmonary Fibrosis
A Phase 2 study of Pulmonary Fibrosis, sponsored by Peter Caravan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06532071 is a Phase 2 study of Pulmonary Fibrosis that is actively recruiting participants, run by Peter Caravan. The registered enrollment target is 60 participants, below the 886-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06532071, a Phase 2 study of Pulmonary Fibrosis, is actively recruiting participants, sponsored by Peter Caravan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.
Conditions Studied
Interventions
- DRUG [68Ga]CBP8
- DRUG Gadoterate Meglumine
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06532071
The ClinicalTrials.gov registry entry for NCT06532071 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 886-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The listed sponsor is Peter Caravan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which [68Ga]CBP8 is the first listed.
NCT06532071 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06532071 about?
NCT06532071 is a clinical study titled "Advanced Imaging for Pulmonary Fibrosis". The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-...
What is the current status of trial NCT06532071?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-01-21. Estimated completion is 2028-12-31.
What conditions does trial NCT06532071 study?
This clinical trial studies the following conditions: Pulmonary Fibrosis.
What interventions are being tested in trial NCT06532071?
The interventions under investigation include: [68Ga]CBP8 (DRUG), Gadoterate Meglumine (DRUG).
Who is sponsoring clinical trial NCT06532071?
This trial is sponsored by Peter Caravan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06532071 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
FAPI PET for Lung Fibrosis
RECRUITING · Early Phase 1
-
Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
RECRUITING
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.